{"id":"NCT06444165","sponsor":"Eli Lilly and Company","briefTitle":"Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis","officialTitle":"Study to Assess Lebrikizumab Pen Ease of Use in Patients With Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2024-06-04","primaryCompletion":"2024-06-10","completion":"2024-06-10","firstPosted":"2024-06-05","resultsPosted":"2025-07-29","lastUpdate":"2025-07-29"},"enrollment":55,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Lebrikizumab Pen","otherNames":[]}],"arms":[{"label":"Lebrikizumab Pen","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the ease of use of the lebrikizumab pen. Participants will use a practice pad to simulate administration of a dose. Participants will complete the modified Subcutaneous Administration Assessment Questionnaire (mSQAAQ) following the simulated injection.\n\nThis study involves one study visit.","primaryOutcome":{"measure":"Percentage of Participants Who Responded Agree or Strongly Agree to the 'Overall Ease of Use' Question Using the Modified Subcutaneous Administration Assessment Questionnaire (mSQAAQ)","timeFrame":"Day 1","effectByArm":[{"arm":"Lebrikizumab Pen","deltaMin":96.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":55},"commonTop":[]}}